Adagene (ADAG) Projected to Post Quarterly Earnings on Thursday

Adagene (NASDAQ:ADAG) is expected to be issuing its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.33) per share for the quarter.

Adagene Stock Up 5.0 %

Shares of NASDAQ ADAG opened at $1.77 on Tuesday. The business has a fifty day moving average price of $1.88 and a two-hundred day moving average price of $2.19. Adagene has a fifty-two week low of $1.64 and a fifty-two week high of $3.58.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Morgan Stanley downgraded Adagene from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 31st. HC Wainwright raised their target price on shares of Adagene from $5.00 to $8.00 and gave the company a “buy” rating in a report on Monday, January 27th.

Adagene Company Profile

Adagene Inc, a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors.